Serological immunoreactivity against colon cancer proteome varies upon disease progression

Lucia De Monte, Francesca Sanvito, Stefano Olivieri, Fiammetta Viganò, Claudio Doglioni, Matteo Frasson, Marco Braga, Angela Bachi, Paolo Dellabona, Maria Pia Protti, Massimo Alessio

Research output: Contribution to journalArticlepeer-review


Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.

Original languageEnglish
Pages (from-to)504-514
Number of pages11
JournalJournal of Proteome Research
Issue number2
Publication statusPublished - Feb 2008


  • 2D electrophoresis
  • Colorectal carcinoma
  • Proteomics
  • Tumor-associated antigens

ASJC Scopus subject areas

  • Genetics
  • Biotechnology
  • Biochemistry


Dive into the research topics of 'Serological immunoreactivity against colon cancer proteome varies upon disease progression'. Together they form a unique fingerprint.

Cite this